About Compass Therapeutics, Inc. - Common Stock (CMPX)
Compass Therapeutics is a biotechnology company dedicated to developing innovative therapies for cancer and other serious diseases. The company focuses on harnessing the power of the immune system to create novel treatment options that target specific pathways involved in tumor growth and immune response. By employing a combination of advanced technologies and comprehensive research, Compass Therapeutics aims to deliver transformative medicines that improve patient outcomes and address unmet medical needs in oncology. Their pipeline includes a range of therapeutic candidates that are designed to enhance the immune system's ability to fight cancer effectively. Read More
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. (“Compass” or the “Company”) (NASDAQ: CMPX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Compass Therapeutics reports Q2 2025 results with a wider-than-expected loss but shows progress in clinical trials for oncology treatments. Market reacts mixedly.
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Momentum investors seek to take advantage of share price rallies to buy companies before they peak; analysts think these three firms still have room to grow.
